HPK1-IN-62

HPK1-IN-62 is a selective and orally active HPK-1 inhibitor with an IC50 of 1.22 nM. HPK1-IN-62 significantly improves GLK selectivity (> 665-fold) and LCK selectivity (> 1095-fold) . HPK1-IN-62 enhances T-cell activation and demonstrated synergistic effects when combined with anti-mPD-1 therapy in the MC38 tumor model, inhibiting a tumor growth. HPK1-IN-62 can be used in the researchs of colon cancer and cancer immunotherapy[1].

Product Specifications

UNSPSC

12352005

Target

MAP4K

Related Pathways

MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

N#CC1=C2C=C(NC3=NC(N[C@@H](C4=C(OCCCC2)C=CC=C4)CO)=C(C=N3)C5=CC(N6CC[C@H](C6)O)=NC=C5)C=C1

Molecular Formula

C32H33N7O3

Molecular Weight

563.65

References & Citations

[1]Duan CX, et al. Design, synthesis, and biological evaluation of 2-substituted-pyridin-4-yl macrocyclic derivatives as new selective HPK1 inhibitors. Bioorg Chem. 2025 Aug 27;165:108925.